US20050220862A1 - Compositions with reduced hepatotoxicity - Google Patents

Compositions with reduced hepatotoxicity Download PDF

Info

Publication number
US20050220862A1
US20050220862A1 US10/813,760 US81376004A US2005220862A1 US 20050220862 A1 US20050220862 A1 US 20050220862A1 US 81376004 A US81376004 A US 81376004A US 2005220862 A1 US2005220862 A1 US 2005220862A1
Authority
US
United States
Prior art keywords
composition
amount
standard dose
per standard
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/813,760
Inventor
Joel Bernstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Winston Laboratories Inc
Original Assignee
Winston Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winston Laboratories Inc filed Critical Winston Laboratories Inc
Priority to US10/813,760 priority Critical patent/US20050220862A1/en
Assigned to WINSTON LABORATORIES, INC. reassignment WINSTON LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERNSTEIN, JOEL E.
Priority to JP2007506267A priority patent/JP2007530688A/en
Priority to PCT/US2005/009795 priority patent/WO2005097120A1/en
Priority to CA002561619A priority patent/CA2561619A1/en
Priority to KR1020067020315A priority patent/KR20070003995A/en
Priority to EP05731289A priority patent/EP1729769A4/en
Publication of US20050220862A1 publication Critical patent/US20050220862A1/en
Priority to US13/197,581 priority patent/US9238017B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Definitions

  • compositions of pharmaceutical compounds having hepatotoxicity in which compositions the hepatotoxicity is mitigated. More particularly, this invention relates to compositions of hepatotoxic compounds such as acetaminophen, methotrexate, statin drugs, niacin, divalproex sodium, valproic acid or fluconazole, each of which is known to have hepatotoxic properties, in which compositions the hepatotoxicity of the compound is mitigated.
  • hepatotoxic compounds such as acetaminophen, methotrexate, statin drugs, niacin, divalproex sodium, valproic acid or fluconazole, each of which is known to have hepatotoxic properties, in which compositions the hepatotoxicity of the compound is mitigated.
  • Acetaminophen is the active metabolite of phenacetin, a drug whose use extends back to the 1880's. Although acetaminophen was first used as an analgesic and antipyretic in 1893, it did not achieve widespread use until after 1949. For many years, acetaminophen was used as a second-line choice to aspirin as an analgesic/antipyretic, but the elucidation of the relationship between aspirin use and Reye's Syndrome and the recognition of aspirin's propensity to produce gastrointestinal bleeding vaulted acetaminophen into its current day position as the analgesic/antipyretic of first choice in both children and adults.
  • acetaminophen While acetaminophen is usually well tolerated, its use can be accompanied by a very serious adverse effect—potentially fatal hepatic necrosis. Hepatic necrosis with acetaminophen is largely confined to two groups of patients: 1. Patients who ingest acute overdoses or who chronically utilize high dosage regimens of acetaminophen. 2. Ingestion of acetaminophen by alcoholics or in combination with alcohol ingestion. It has been reported that more than 26,000 patients per year are hospitalized in the U.S. for acetaminophen induced hepatic necroses, and of these, more than 400 die each year.
  • Methotrexate an inhibitor of cell metabolism, has been utilized for several decades as a therapeutic agent widely used in several different diseases including rheumatoid arthritis and psoriasis. While methotrexate administration is associated with various other side effects, severe and sometimes fatal liver toxicity is a significant limiting factor in its therapeutic usefulness. Atorvastatin, simvastatin and other cholesterol reducing agents of the “statin” family are the most widely used pharmaceuticals in the world. In spite of their widespread use, liver toxicity is a significant problem, and patients with a history of old or active hepatitis must avoid these drugs even if they could benefit from their cholesterol lowering actions.
  • Niacin also known as nicotinic acid or vitamin B 3
  • Fluconazole a potent antifungal agent
  • divalproex sodium and valproic acid widely used antiepileptics are three other agents whose clinical use is limited by their hepatotoxicity.
  • nicotinamide also known as niacinamide
  • methionine an essential amino acid which is a DL racemic mixture of D & L methionine
  • nicotinamide and methionine can be administered in combination with hepatotoxic pharmaceutical compounds such as acetaminophen, methotrexate, a “statin” cholesterol lowering agent, fluconazole, divalproex sodium or valproic acid, in substantially lower doses than disclosed in the prior art, and when administered as such, can provide a substantive protective effect against the hepatotoxicity of these agents without negatively affecting their beneficial therapeutic activity.
  • hepatotoxic pharmaceutical compounds such as acetaminophen, methotrexate, a “statin” cholesterol lowering agent, fluconazole, divalproex sodium or valproic acid
  • hepatotoxic pharmaceutical compounds such as acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium, valproic acid, and related drugs
  • compositions of hepatotoxic therapeutic drugs such as acetaminophen, methotrexate, the “statins,” niacin, fluconazole, divalproex sodium, valproic acid, and related drugs, which compositions provide the therapeutic benefits of the active drug with markedly reduced potential for serious hepatotoxicity.
  • compositions in which the hepatotoxic properties are mitigated.
  • the compositions can include a standard dose of the hepatotoxic compound, together with relatively low dosages of nicotinamide and methionine. Low dosages of folic acid also can be added to the compositions to further mitigate the hepatotoxic properties.
  • Specific embodiments of the invention can be in the form of formulations of acetaminophen together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid; or formulations of methotrexate together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid.
  • These formulations are incorporated into pharmaceutically acceptable vehicles for use in humans and animals.
  • formulations of atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium or valproic acid each can be formulated into pharmaceutically acceptable vehicles for use in humans and animals together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid.
  • Such formulations include those suitable for oral administration such as capsules, tablets, caplets, or liquid solutions or suspensions, as well as sterile solutions or suspensions suitable for intradermal, subcutaneous, intramuscular, intravenous or intrathecal injection.
  • acetaminophen 80 mg-1000 mg per single dose form, e.g. single capsule, single tablet, etc.
  • methotrexate 2.5 mg-250 mg per single dose form
  • atorvastatin or simvastatin 5 mg-100 mg per single dose form
  • niacin 250 mg-1000 mg per single dose form
  • fluconazole 10 mg-250 mg per single dose form
  • divalproex sodium 100 mg-750 mg per single dose form
  • valproic acid 25 mg-500 mg per single dose form
  • methionine may be present in the amount of about 5 mg to about 500 mg per single dose form, and preferably about 10 mg to 100 mg per single dose form
  • nicotinamide may be present in the amount of about 10 mg to 500 mg per single dose form, and preferably about 25 mg to about 200 mg per single dose form.
  • Suitable pharmaceutical vehicles for the combinations of hepatotoxic compounds such as acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium or valproic acid, with hepatotoxicity mitigators methionine, nicotinamide and folic acid, and methods of preparing such formulations as are within the scope of the invention, will be readily apparent to and understood by those skilled in the art.
  • compositions of the instant invention will be more readily comprehended from the following examples:
  • Two tablets comprised of 500 mg acetaminophen, 50 mg methionine, and 25 mg nicotinamide, are administered to patients with painful osteoarthritis four times daily for 12 weeks producing substantial relief of joint pain without evidence of any hepatotoxicity.
  • Capsules are prepared each containing by weight 325 mg acetaminophen, 50 mg methionine, 50 mg nicotinamide, and 500 mcg folic acid.
  • One to two of such capsules are administered to patients with osteoarthritis or fibromyalgia pain four to six times daily for 6 months for relief of joint or soft tissue pain without evidence of damage to the patients' livers.
  • Two caplets each containing 500 mg acetaminophen, 200 mg methionine, and 100 mg nicotinamide are administered four times daily for twelve (12) weeks to patients with osteoarthritis for relief of osteoarthritis pain without evidence of liver damage.
  • Tablets are prepared each containing 2.5 mg methotrexate, 100 mg methionine, 100 mg nicotinamide and 100 mcg folic acid. Two of such tablets are administered to patients with psoriasis of the skin twice daily for 6 months. Such patients demonstrate improvement in their psoriatic lesions without evidence of serious methotrexate-induced liver damage.
  • Tablets containing 250 mg divalproex sodium, 250 mg methionine and 100 mg nicotinamide by weight are administered twice daily to patients with migraine headaches to prevent or diminish the severity of migraine headaches without evidence of serious liver damage.
  • Capsules are prepared each containing by weight 10 mg atorvastatin, 500 mg methionine, 100 mg nicotinamide, and 1.0 mg folic acid and administered to patients once daily. Such patients have lower serum cholesterol and triglycerides without vidence of significant alteration in their liver functions.
  • An oral suspension containing 10 mg/ml fluconazole, 25 mg/ml methionine and 20 mg/ml nicotinamide is administered to children for treatment of oropharyngeal candidiasis at a dosage of 2-12 mg/kg per day for 3 weeks with a substantially lessened risk of liver toxicity than with standard fluconazole suspensions.

Abstract

Pharmaceutical compositions of hepatotoxic compounds are provided in which the hepatotoxicity of the compounds is mitigated by including quantities of nicotinamide and methionine in the composition. Folic acid also can be included to further mitigate the hepatotoxic effects. The hepatotoxic compounds can include acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanozole, divalproex sodium, and valproic acid.

Description

    BACKGROUND OF THE INVENTION
  • This invention relates to compositions of pharmaceutical compounds having hepatotoxicity, in which compositions the hepatotoxicity is mitigated. More particularly, this invention relates to compositions of hepatotoxic compounds such as acetaminophen, methotrexate, statin drugs, niacin, divalproex sodium, valproic acid or fluconazole, each of which is known to have hepatotoxic properties, in which compositions the hepatotoxicity of the compound is mitigated.
  • Acetaminophen is the active metabolite of phenacetin, a drug whose use extends back to the 1880's. Although acetaminophen was first used as an analgesic and antipyretic in 1893, it did not achieve widespread use until after 1949. For many years, acetaminophen was used as a second-line choice to aspirin as an analgesic/antipyretic, but the elucidation of the relationship between aspirin use and Reye's Syndrome and the recognition of aspirin's propensity to produce gastrointestinal bleeding vaulted acetaminophen into its current day position as the analgesic/antipyretic of first choice in both children and adults. While acetaminophen is usually well tolerated, its use can be accompanied by a very serious adverse effect—potentially fatal hepatic necrosis. Hepatic necrosis with acetaminophen is largely confined to two groups of patients: 1. Patients who ingest acute overdoses or who chronically utilize high dosage regimens of acetaminophen. 2. Ingestion of acetaminophen by alcoholics or in combination with alcohol ingestion. It has been reported that more than 26,000 patients per year are hospitalized in the U.S. for acetaminophen induced hepatic necroses, and of these, more than 400 die each year. Many of these overdoses are the result of suicide attempts, but reports indicate that more than 2,000 hospitalizations and 100 deaths a year were attributable to non-intentional acetaminophen overdoses. In fact, an Advisory Panel of the U.S. Food and Drug Administration has recommended that new warning language be added to the label of acetaminophen containing products concerning the danger of hepatic necroses.
  • Methotrexate, an inhibitor of cell metabolism, has been utilized for several decades as a therapeutic agent widely used in several different diseases including rheumatoid arthritis and psoriasis. While methotrexate administration is associated with various other side effects, severe and sometimes fatal liver toxicity is a significant limiting factor in its therapeutic usefulness. Atorvastatin, simvastatin and other cholesterol reducing agents of the “statin” family are the most widely used pharmaceuticals in the world. In spite of their widespread use, liver toxicity is a significant problem, and patients with a history of old or active hepatitis must avoid these drugs even if they could benefit from their cholesterol lowering actions. Niacin (also known as nicotinic acid or vitamin B3), another agent frequently employed as a cholesterol lowering agent, is also associated with a high incidence of liver toxicity. Fluconazole, a potent antifungal agent, and divalproex sodium and valproic acid, widely used antiepileptics are three other agents whose clinical use is limited by their hepatotoxicity.
  • The concerns about the hepatic toxicity of acetaminophen, methotrexate, the “statin” cholesterol lowering agents, niacin, fluconazole, divalproex sodium and valproic acid, prompted me to search for a substitute or a mixture of substances that in combination with any of these drugs would substantially reduce the risk of hepatic toxicity without adversely affecting the therapeutic benefits conferred by these drugs. In reviewing the scientific literature, I learned that nicotinamide (also known as niacinamide), which is the amide of vitamin B3 (niacin), and methionine, an essential amino acid which is a DL racemic mixture of D & L methionine, have been used in very high dosages to prevent liver damage from acetaminophen or methotrexate. These drugs have been administered as single large doses or multiple large doses over a short (usually 24 hr) period. Published dosages of methionine for such usage range from about 2.5 gm to over 21 gm administered as a single dose for over 24 hours. Wright, B., Crowe, M., British Medical Journal (England), vol. 317, Dec. 12, 1998, p. 1656; Vale, J. A., Proudfoot, A. T., The Lancet, 1995, vol. 346, pp. 547-52. Similarly, doses of nicotinamide utilized for a similar purpose have ranged from about 2 gm to 7 gm per 24 hours. Kroger, H., et al., General Pharmacology 33 (1999) 203-206.
  • I have discovered, surprisingly, that nicotinamide and methionine can be administered in combination with hepatotoxic pharmaceutical compounds such as acetaminophen, methotrexate, a “statin” cholesterol lowering agent, fluconazole, divalproex sodium or valproic acid, in substantially lower doses than disclosed in the prior art, and when administered as such, can provide a substantive protective effect against the hepatotoxicity of these agents without negatively affecting their beneficial therapeutic activity. I have furthermore discovered that by adding a modest amount of folic acid to the nicotinamide and methionine mixture, in combination with hepatotoxic pharmaceutical compounds such as acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium, valproic acid, and related drugs, I can achieve a therapeutic product which provides the therapeutic benefits of each of these agents with almost no potential for liver toxicity.
  • It is thus the object of the invention to provide pharmaceutically acceptable compositions of hepatotoxic therapeutic drugs such as acetaminophen, methotrexate, the “statins,” niacin, fluconazole, divalproex sodium, valproic acid, and related drugs, which compositions provide the therapeutic benefits of the active drug with markedly reduced potential for serious hepatotoxicity.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • In accordance with the invention, compounds having known hepatotoxic properties are formulated into compositions in which the hepatotoxic properties are mitigated. The compositions can include a standard dose of the hepatotoxic compound, together with relatively low dosages of nicotinamide and methionine. Low dosages of folic acid also can be added to the compositions to further mitigate the hepatotoxic properties.
  • Specific embodiments of the invention can be in the form of formulations of acetaminophen together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid; or formulations of methotrexate together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid. These formulations are incorporated into pharmaceutically acceptable vehicles for use in humans and animals. Similarly, formulations of atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium or valproic acid each can be formulated into pharmaceutically acceptable vehicles for use in humans and animals together with mixtures of low dosages of nicotinamide and methionine, or together with low dosages of nicotinamide, methionine and folic acid. Such formulations include those suitable for oral administration such as capsules, tablets, caplets, or liquid solutions or suspensions, as well as sterile solutions or suspensions suitable for intradermal, subcutaneous, intramuscular, intravenous or intrathecal injection.
  • In each of the foregoing formulations, whether for oral ingestion or for injection, when combined with standard dosages of either acetaminophen (80 mg-1000 mg per single dose form, e.g. single capsule, single tablet, etc.), methotrexate (2.5 mg-250 mg per single dose form), atorvastatin or simvastatin (5 mg-100 mg per single dose form), niacin (250 mg-1000 mg per single dose form), fluconazole (10 mg-250 mg per single dose form), divalproex sodium (100 mg-750 mg per single dose form), and valproic acid (25 mg-500 mg per single dose form), methionine may be present in the amount of about 5 mg to about 500 mg per single dose form, and preferably about 10 mg to 100 mg per single dose form, and nicotinamide may be present in the amount of about 10 mg to 500 mg per single dose form, and preferably about 25 mg to about 200 mg per single dose form. When folic acid is included in the standard dose formulation, folic acid may be present in the amount of about 50 mcg to about 5 mg, and preferably about 500 mcg to 1 mg, per single dose form.
  • Suitable pharmaceutical vehicles for the combinations of hepatotoxic compounds such as acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium or valproic acid, with hepatotoxicity mitigators methionine, nicotinamide and folic acid, and methods of preparing such formulations as are within the scope of the invention, will be readily apparent to and understood by those skilled in the art.
  • The compositions of the instant invention will be more readily comprehended from the following examples:
    • EXAMPLES Example 1
  • Two tablets, comprised of 500 mg acetaminophen, 50 mg methionine, and 25 mg nicotinamide, are administered to patients with painful osteoarthritis four times daily for 12 weeks producing substantial relief of joint pain without evidence of any hepatotoxicity.
    • Example 2
  • Capsules are prepared each containing by weight 325 mg acetaminophen, 50 mg methionine, 50 mg nicotinamide, and 500 mcg folic acid. One to two of such capsules are administered to patients with osteoarthritis or fibromyalgia pain four to six times daily for 6 months for relief of joint or soft tissue pain without evidence of damage to the patients' livers.
    • Example 3
  • Two caplets each containing 500 mg acetaminophen, 200 mg methionine, and 100 mg nicotinamide are administered four times daily for twelve (12) weeks to patients with osteoarthritis for relief of osteoarthritis pain without evidence of liver damage.
    • Example 4
  • Tablets are prepared each containing 2.5 mg methotrexate, 100 mg methionine, 100 mg nicotinamide and 100 mcg folic acid. Two of such tablets are administered to patients with psoriasis of the skin twice daily for 6 months. Such patients demonstrate improvement in their psoriatic lesions without evidence of serious methotrexate-induced liver damage.
    • Example 5
  • Tablets containing 250 mg divalproex sodium, 250 mg methionine and 100 mg nicotinamide by weight are administered twice daily to patients with migraine headaches to prevent or diminish the severity of migraine headaches without evidence of serious liver damage.
    • Example 6
  • Capsules are prepared each containing by weight 10 mg atorvastatin, 500 mg methionine, 100 mg nicotinamide, and 1.0 mg folic acid and administered to patients once daily. Such patients have lower serum cholesterol and triglycerides without vidence of significant alteration in their liver functions.
    • Example 7
  • An oral suspension containing 10 mg/ml fluconazole, 25 mg/ml methionine and 20 mg/ml nicotinamide is administered to children for treatment of oropharyngeal candidiasis at a dosage of 2-12 mg/kg per day for 3 weeks with a substantially lessened risk of liver toxicity than with standard fluconazole suspensions.

Claims (37)

1. A composition comprising one or more standard doses of a hepatotoxic compound in a pharmaceutically acceptable carrier, the composition further comprising about 5 mg to about 500 mg methionine per standard dose and about 10 mg to about 500 mg nicotinamide per standard dose.
2. The composition of claim 1 wherein said composition is suitable for oral ingestion.
3. The composition of claim 2 wherein said composition is selected from the group consisting of solutions, suspensions, tablets, capsules and caplets.
4. The composition of claim 1 wherein said composition is suitable for injection.
5. The composition of claim 4 wherein said composition is selected from the group consisting of sterile solutions or suspensions.
6. The composition of claim 5 wherein said composition is suitable for intradermal, subcutaneous, intramuscular, intravenous or intrathecal injection.
7. The composition of claim 1 wherein said composition also contains folic acid in an amount of about 50 mcg to about 5 mg per standard dose.
8. The composition of claim 7 wherein said composition is suitable for oral ingestion.
9. The composition of claim 8 wherein said composition is selected from the group consisting of solutions, suspensions, tablets, capsules and caplets.
10. The composition of claim 7 wherein said composition is suitable for injection.
11. The composition of claim 10 wherein said composition is selected from the group consisting of sterile solutions or suspensions.
12. The composition of claim 11 wherein said composition is suitable for intradermal, subcutaneous, intramuscular, intravenous, or intrathecal injection.
13. The composition of claim 1 wherein said hepatotoxic compound is selected from the group consisting of acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanozole, divalproex sodium, and valproic acid.
14. The composition of claim 13 wherein said hepatotoxic compound is acetaminophen.
15. The composition of claim 14 wherein said acetaminophen is present in the amount of about 80-1000 mg per standard dose.
16. The composition of claim 13 wherein said hepatotoxic compound is methotrexate.
17. The composition of claim 16 wherein said methotrexate is present in the amount of about 25-250 mg per standard dose.
18. The composition of claim 13 wherein said hepatotoxic compound is atorvastatin.
19. The composition of claim 18 wherein said atorvastatin is present in the amount of about 5-100 mg per standard dose per standard dose.
20. The composition of claim 13 wherein said hepatotoxic compound is simvastatin.
21. The composition of claim 20 wherein said simvastatin is present in the amount of about 5-100 mg per standard dose.
22. The composition of claim 13 wherein said hepatotoxic compound is niacin.
23. The composition of claim 22 wherein said niacin is present in the amount of about 250-1000 mg per standard dose.
24. The composition of claim 13 wherein said hepatotoxic compound is flucanozole.
25. The composition of claim 24 wherein said flucanozole is present in the amount of about 10-250 mg per standard dose.
26. The composition of claim 13 wherein said hepatotoxic compound is divalproex sodium.
27. The composition of claim 26 wherein said divalproex sodium is present in the amount of 100-750 mg per standard dose.
28. The composition of claim 13 wherein said hepatotoxic compound is valproic acid.
29. The composition of claim 28 wherein said valproic acid is present in the amount of 25-500 mg per standard dose.
30. A method of mitigating the hepatotoxicity of a hepatotoxic compound comprising formulating a composition comprising a quantity of the hepatotoxic compound, said composition comprising a quantity of nicotinamide, and a quantity of methionine.
31. The method of claim 30 wherein said composition is formulated such that for each standard dose of the hepatotoxic compound in the composition, the nicotinamide is present in the amount of about 5-500 mg, and the methionine is present in the amount of about 25-500 mg.
32. The method of claim 31 wherein said nicotinamide is present in the amount of about 25-200 mg per standard dose of the hepatotoxic compound.
33. The method of claim 31 wherein said methionine is present in the amount of about 10-100 mg per standard dose of the hepatotoxic compound.
34. The method of claim 30 wherein said composition further comprises a quantity of folic acid.
35. The method of claim 34 wherein said folic acid is present in the amount of about 50 mcg-5 mg per standard dose of the hepatotoxic compound.
36. The method of claim 35 wherein said folic acid is present in the amount of about 500 mg-1 mg per standard dose of the hepatotoxic compound.
37. The method of claim 30 wherein said hepatotoxic compound is selected from the group consisting of acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanozole, divalproex sodium, and valproic acid.
US10/813,760 2004-03-31 2004-03-31 Compositions with reduced hepatotoxicity Abandoned US20050220862A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/813,760 US20050220862A1 (en) 2004-03-31 2004-03-31 Compositions with reduced hepatotoxicity
JP2007506267A JP2007530688A (en) 2004-03-31 2005-03-23 Composition with reduced hepatotoxicity
PCT/US2005/009795 WO2005097120A1 (en) 2004-03-31 2005-03-23 Compositions with reduced hepatotoxicity
CA002561619A CA2561619A1 (en) 2004-03-31 2005-03-23 Compositions with reduced hepatotoxicity
KR1020067020315A KR20070003995A (en) 2004-03-31 2005-03-23 Compositions with reduced hepatotoxicity
EP05731289A EP1729769A4 (en) 2004-03-31 2005-03-23 Compositions with reduced hepatotoxicity
US13/197,581 US9238017B2 (en) 2004-03-31 2011-08-03 Compositions with reduced hepatotoxicity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/813,760 US20050220862A1 (en) 2004-03-31 2004-03-31 Compositions with reduced hepatotoxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/197,581 Division US9238017B2 (en) 2004-03-31 2011-08-03 Compositions with reduced hepatotoxicity

Publications (1)

Publication Number Publication Date
US20050220862A1 true US20050220862A1 (en) 2005-10-06

Family

ID=35054591

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/813,760 Abandoned US20050220862A1 (en) 2004-03-31 2004-03-31 Compositions with reduced hepatotoxicity
US13/197,581 Active 2024-09-25 US9238017B2 (en) 2004-03-31 2011-08-03 Compositions with reduced hepatotoxicity

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/197,581 Active 2024-09-25 US9238017B2 (en) 2004-03-31 2011-08-03 Compositions with reduced hepatotoxicity

Country Status (6)

Country Link
US (2) US20050220862A1 (en)
EP (1) EP1729769A4 (en)
JP (1) JP2007530688A (en)
KR (1) KR20070003995A (en)
CA (1) CA2561619A1 (en)
WO (1) WO2005097120A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080015893A1 (en) * 2006-07-17 2008-01-17 Walgreen Co. Identification of Inappropriate Medications In A Medication Therapy Regimen
US20080097784A1 (en) * 2006-07-17 2008-04-24 Walgreen Co. Appropriateness Of A Medication Therapy Regimen
US20080126130A1 (en) * 2006-07-17 2008-05-29 Walgreen Co. Compliance With A Medication Therapy Regimen
US20080126117A1 (en) * 2006-07-17 2008-05-29 Walgreen Co. Optimization Of A Medication Therapy Regimen
WO2023144118A1 (en) * 2022-01-25 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of therapy comprising simultaneous administration of methotrexate and folic acid

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705131C (en) * 2007-11-29 2016-06-28 Alltranz Inc. Methods and compositions for enhancing the viability of microneedle pores
ITMI20080187A1 (en) * 2008-02-07 2009-08-08 Velleja Res Srl AMINO ACID FORMULATIONS FOR THE PREVENTION OF HEPATIC PARACETAMOL DAMAGE
WO2012090218A1 (en) * 2010-12-30 2012-07-05 Zota Health Care Ltd Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases
CN106390130B (en) * 2016-09-18 2018-06-01 中国人民解放军第二军医大学 Purposes of the niacinamide as antifungal medicine synergist

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983250A (en) * 1974-10-02 1976-09-28 The Dow Chemical Company Halophenyl acetamidines as anxiolytic antidepressants
US4181719A (en) * 1977-05-26 1980-01-01 Sterling Drug Inc. Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US4401657A (en) * 1980-12-27 1983-08-30 Snow Brand Milk Products Co., Ltd. Nutrient composition suitable for enteral feeding
US4526788A (en) * 1983-03-18 1985-07-02 American Cyanamid Company Polymeric[[(oxazolidinyl)alkyl]amino]anthraquinones
US4581348A (en) * 1983-07-11 1986-04-08 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Synergistic pharmaceutical compositions
US4656159A (en) * 1984-10-31 1987-04-07 Georgetown University Galactose-C-6 nitrogen mustard compounds and their uses
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5059592A (en) * 1987-07-29 1991-10-22 Fujisawa Pharmaceutical Co., Ltd. Composition for prevention and (or) treatment of AIDS
US5284861A (en) * 1990-07-14 1994-02-08 Asta Medica Ag Pharmaceutical composition comprising flupirtine and its use to combat Parkinson disorders
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5478815A (en) * 1993-12-02 1995-12-26 Senji Pharmaceutical Co., Ltd. Liver protectant tocophery-ascorbyl-phosphate
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
US5994410A (en) * 1995-10-26 1999-11-30 National Science Council Therapeutic use of water-soluble fullerene derivatives
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6465511B1 (en) * 1993-05-06 2002-10-15 Molichem Medicines, Inc. Treatment of septic shock
US6468967B1 (en) * 1998-09-25 2002-10-22 Cubist Pharmaceuticals, Incorporated Methods for administration of antibiotics
US6673831B1 (en) * 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6733797B1 (en) * 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
US6881401B1 (en) * 1996-10-25 2005-04-19 Human Genome Sciences, Inc. Methods of treatment of immune system related disorders using Neutrokine-alpha
US7371388B1 (en) * 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US20090124606A1 (en) * 2005-07-14 2009-05-14 Istvan Gacsalyi Composition for Treatment of Psychosis
US7557142B2 (en) * 1996-10-03 2009-07-07 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine to reduce the toxicity of platinum-containing anti-tumor compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850429T2 (en) * 1987-03-26 1994-11-24 Univ London Prevention of ADP ribosylation of G proteins.
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983250A (en) * 1974-10-02 1976-09-28 The Dow Chemical Company Halophenyl acetamidines as anxiolytic antidepressants
US4181719A (en) * 1977-05-26 1980-01-01 Sterling Drug Inc. Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US4401657A (en) * 1980-12-27 1983-08-30 Snow Brand Milk Products Co., Ltd. Nutrient composition suitable for enteral feeding
US4526788A (en) * 1983-03-18 1985-07-02 American Cyanamid Company Polymeric[[(oxazolidinyl)alkyl]amino]anthraquinones
US4581348A (en) * 1983-07-11 1986-04-08 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Synergistic pharmaceutical compositions
US4656159A (en) * 1984-10-31 1987-04-07 Georgetown University Galactose-C-6 nitrogen mustard compounds and their uses
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5059592A (en) * 1987-07-29 1991-10-22 Fujisawa Pharmaceutical Co., Ltd. Composition for prevention and (or) treatment of AIDS
US5284861A (en) * 1990-07-14 1994-02-08 Asta Medica Ag Pharmaceutical composition comprising flupirtine and its use to combat Parkinson disorders
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US6465511B1 (en) * 1993-05-06 2002-10-15 Molichem Medicines, Inc. Treatment of septic shock
US5478815A (en) * 1993-12-02 1995-12-26 Senji Pharmaceutical Co., Ltd. Liver protectant tocophery-ascorbyl-phosphate
US5994410A (en) * 1995-10-26 1999-11-30 National Science Council Therapeutic use of water-soluble fullerene derivatives
US6673831B1 (en) * 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
US7557142B2 (en) * 1996-10-03 2009-07-07 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6881401B1 (en) * 1996-10-25 2005-04-19 Human Genome Sciences, Inc. Methods of treatment of immune system related disorders using Neutrokine-alpha
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6468967B1 (en) * 1998-09-25 2002-10-22 Cubist Pharmaceuticals, Incorporated Methods for administration of antibiotics
US7371388B1 (en) * 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US6733797B1 (en) * 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
US20090124606A1 (en) * 2005-07-14 2009-05-14 Istvan Gacsalyi Composition for Treatment of Psychosis

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080015893A1 (en) * 2006-07-17 2008-01-17 Walgreen Co. Identification of Inappropriate Medications In A Medication Therapy Regimen
US20080097784A1 (en) * 2006-07-17 2008-04-24 Walgreen Co. Appropriateness Of A Medication Therapy Regimen
US20080126130A1 (en) * 2006-07-17 2008-05-29 Walgreen Co. Compliance With A Medication Therapy Regimen
US20080126117A1 (en) * 2006-07-17 2008-05-29 Walgreen Co. Optimization Of A Medication Therapy Regimen
US8478605B2 (en) 2006-07-17 2013-07-02 Walgreen Co. Appropriateness of a medication therapy regimen
US8700430B2 (en) 2006-07-17 2014-04-15 Walgreen Co. Optimization of a medication therapy regimen
WO2023144118A1 (en) * 2022-01-25 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of therapy comprising simultaneous administration of methotrexate and folic acid

Also Published As

Publication number Publication date
KR20070003995A (en) 2007-01-05
CA2561619A1 (en) 2005-10-20
WO2005097120A1 (en) 2005-10-20
EP1729769A1 (en) 2006-12-13
EP1729769A4 (en) 2008-11-05
US20110288099A1 (en) 2011-11-24
JP2007530688A (en) 2007-11-01
US9238017B2 (en) 2016-01-19

Similar Documents

Publication Publication Date Title
US9238017B2 (en) Compositions with reduced hepatotoxicity
US5331000A (en) Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
JP2015078185A (en) N-acetylcysteine composition and method for treatment and prevention of drug toxicity
CA2892902C (en) Entacapone for prevention and treatment of obesity and related metabolic diseases
EP2141155B1 (en) Prophylactic and/or therapeutic agent for hyperlipidemia
EP0710108A1 (en) Liquid pharmaceutical composition for oral use containing 2-(4-isobutylphenyl)propionic acid
JP3797764B2 (en) Light stabilizing composition
US6048540A (en) Acetamenophen composition with reduced liver toxicity
CA3032453A1 (en) Pharmaceutical formulations and their use
JP2004083579A (en) Antipyretic composition
TW200300341A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
JP5376785B2 (en) Pharmaceutical composition
JP2012176899A (en) Aqueous solution for injection, containing 2-(1-piperazinyl)-5-methylbenzene sulfonic acid derivative
KR102427941B1 (en) Injectable formulation with enhanced stability containing ibuprofen and afginine
JP2007077116A (en) Organ fiberization inhibitor
CN113116899B (en) Pharmaceutical composition for treating influenza and preparation containing pharmaceutical composition
JP5366386B2 (en) Nerve cell activation and nerve elongation promoting composition
KR100983990B1 (en) Medicinal composition for inhibiting the expression of ATP-citrate lyase
IE913185A1 (en) Method for providing improved analgesic effect
JPS63267727A (en) Drug comprising s-lactoylglutathione and/or salt thereof as active ingredient
EP0083378A1 (en) Tetrahydronicotinamide derivatives, a process for producing the same and a pharmaceutical composition comprising the same
JPH06102624B2 (en) Anti-arrhythmic drugs of non-heart origin
EP2638902B1 (en) Antimalarial drug comprising alaremycin or derivative thereof as active ingredient
JPH072661A (en) Agent for inhibiting secretion myeloperoxidase
JP2005289904A (en) Medicinal composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: WINSTON LABORATORIES, INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BERNSTEIN, JOEL E.;REEL/FRAME:015164/0716

Effective date: 20040331

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION